<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "JATS-journalpublishing1.dtd"[]>
<article xml:lang="en" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.2"  article-type="abstract">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">IJPDS</journal-id>
      <journal-title-group>
        <journal-title>International Journal of Population Data Science</journal-title>
        <abbrev-journal-title>IJPDS</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub">2399-4908</issn>
      <publisher>
        <publisher-name>Swansea University</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.23889/ijpds.v7i3.1787</article-id>
      <article-id pub-id-type="publisher-id">7:03:015</article-id>
      <title-group>
        <article-title>The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018: findings from the OATS retrospective linkage study.</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Jones</surname>
            <given-names initials="N">Nicola</given-names>
          </name>
          <xref ref-type="aff" rid="affil-1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Degenhardt</surname>
            <given-names initials="L">Louisa</given-names>
          </name>
          <xref ref-type="aff" rid="affil-1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hickman</surname>
            <given-names initials="M">Matthew</given-names>
          </name>
          <xref ref-type="aff" rid="affil-2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nielsen</surname>
            <given-names initials="S">Suzanne</given-names>
          </name>
          <xref ref-type="aff" rid="affil-3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Larney</surname>
            <given-names initials="S">Sarah</given-names>
          </name>
          <xref ref-type="aff" rid="affil-4">4</xref>
          <xref ref-type="aff" rid="affil-5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dobbins</surname>
            <given-names initials="T">Timothy</given-names>
          </name>
          <xref ref-type="aff" rid="affil-6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ali</surname>
            <given-names initials="R">Robert</given-names>
          </name>
          <xref ref-type="aff" rid="affil-7">7</xref>
        </contrib>
      </contrib-group>
      <aff id="affil-1"><label>1</label>
        <institution>National Drug and Alcohol Research Centre</institution>
      </aff>
      <aff id="affil-2"><label>2</label>
        <institution>University of Bristol</institution>
      </aff>
      <aff id="affil-3"><label>3</label>
        <institution>Monash University</institution>
      </aff>
      <aff id="affil-4"><label>4</label>
        <institution>Université de Montréal</institution>
      </aff>
      <aff id="affil-5"><label>5</label>
        <institution>Centre de Recherche du Centre Hospitalier de l'Université de Montréal</institution>
      </aff>
      <aff id="affil-6"><label>6</label>
        <institution>University of New South Wales</institution>
      </aff>
      <aff id="affil-7"><label>7</label>
        <institution>The University of Adelaide</institution>
      </aff>
      <pub-date date-type="pub" publication-format="electronic"><day></day><month>09</month><year>2017</year></pub-date>
      <pub-date date-type="collection" publication-format="electronic"><year>2022</year></pub-date>
      <volume>7</volume>
      <issue>3</issue>
      <elocation-id>1787</elocation-id>
      <permissions>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licences/by/4.0/">
          <license-p>This work is licenced under a Creative Commons Attribution 4.0 International License.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="https://ijpds.org/article/view/1787">This article is available from the IJPDS website at: https://ijpds.org/article/view/1787</self-uri>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Objectives</title>
      <p>There are critical periods of mortality risk at onset and cessation of opioid agonist treatment. We aim to determine whether non-fatal overdose followed the same pattern as fatal overdose, comparing the first 4 weeks of treatment and treatment cessation and the remainder time off treatment, with the remainder treatment time, to determine intervention markers.</p>
    </sec>
    <sec>
      <title>Approach</title>
      <p>Retrospective cohort study of people with a history of opioid agonist treatment using linked New South Wales data. The incidence of non-fatal overdose hospitalization; emergency department presentation; and fatal overdose from national death records were compared. Rates were calculated using generalized estimating equations adjusting for demographics, year, and recent health and incarceration events.</p>
    </sec>
    <sec>
      <title>Results</title>
      <p>The rate of an emergency department drug overdose presentation was highest. It was more than three-fold the rate of opioid non-fatal overdose hospitalisation and 14 times higher than fatal opioid overdose. It was also twice the rate of non-opioid non-fatal overdose hospitalisation.</p>
      <p>Fatal overdose was lowest while in treatment. This differed from the measures of non-fatal overdose, the overdose rate was elevated in the first four weeks in treatment as well as the first four weeks post treatment.</p>
    </sec>
    <sec>
      <title>Conclusion</title>
      <p>Retention on opioid agonist treatment is protective against drug related overdose. There is elevated risk of non-fatal overdose at treatment initiation that is not evident for fatal overdose, however the first month of treatment cessation is a critical period for both non-fatal and fatal overdose. These findings emphasize the importance of treatment retention and interventions for polysubstance overdose at cessation.</p>
    </sec>
  </body>
</article>